Glenmede Trust Co. NA Acquires 405,624 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Glenmede Trust Co. NA boosted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 125.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 727,781 shares of the life sciences company’s stock after buying an additional 405,624 shares during the quarter. Glenmede Trust Co. NA owned approximately 0.94% of Integra LifeSciences worth $13,224,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC boosted its position in Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares during the period. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 1,120 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Integra LifeSciences in the 2nd quarter valued at approximately $114,000. Finally, Northwest Investment Counselors LLC bought a new position in shares of Integra LifeSciences during the third quarter valued at $73,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IART shares. Truist Financial decreased their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Finally, Bank of America lowered their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and an average price target of $24.00.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $24.54 on Friday. The stock’s 50 day moving average price is $20.49 and its two-hundred day moving average price is $24.00. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -272.67, a PEG ratio of 0.82 and a beta of 1.08. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million during the quarter, compared to analysts’ expectations of $375.81 million. During the same period last year, the company posted $0.76 earnings per share. The business’s quarterly revenue was down .4% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.